Trevena is a King of Prussia, Pennsylvania-based pharmaceutical company focused on discovering and developing G-protein coupled receptor (GPCR) biased ligands. Its lead molecule, TRV120027, is an angiotensin II type I receptor (AT1R) beta-arrestin biased ligand being developed for treatment of acute heart failure. The company completed a $35M Series B financing to fund its clinical program. The capital infusion will enable Trevena to complete a Phase 2 study of TRV120027 and to continue advancing its portfolio of GPCR biased ligands. The financing was announced on 14 July 2010.

Total raised

$35M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2010